T argeting S phingosine K inase 1 and A poptosis by M etformin to D ecrease T umor R esistance to A driamycin By Dr. Ahmed Mohamed Kabel Pharmacology.

Slides:



Advertisements
Similar presentations
CANCER CHEMOTHERAPY. Anti Cancer drugs: 1.Historically derived small molecules. Target DNA structure or segregation of DNA- Conventional chemotherapy.
Advertisements

Bio 130 Human Biology Cancer Normal cells have regulation that keeps their rates of cell division in check. Normal cells generally remain in one location.
Cancer Cancer originates in dividing cells –Intestinal lining (colon) –Lung tissue –Breast tissue (glands/ducts) –Prostate (gland) –White blood cells.
The Story of Bcl-2 Linking cell apoptosis to tumor metastasis Crystal structure of Bcl-2 complex By Yaming Wang.
118/2/2015 Cancer & the Immune System Hugh B. Fackrell.
Chapter 19 Cancer and the Immune System Dr. Capers.
CELL DIVISION AND CANCER Unit 7 - Mitosis. Mitosis  All cells in your body divide  In children and teens, cells divide to assist in growth  In adults,
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Cancer Chemotherapy Topics
+ How is the cell cycle regulated? Sections 8.8 and 8.9.
Cancer therapy - conventional Surgery Radiotherapy Chemotherapy Adjuvant therapies.
The Cell Nucleus Eukaryotic cells have a membrane-bound cell nucleus. The nucleus contains most of a cell’s genetic material. The genetic material of a.
10.3 Regulating the Cell Cycle
SC430 Molecular Cell Biology
Regulating the Cell Cycle
Chapter 11 Objectives Section 1 Control of Gene Expression
ANTINEOPLASTICS I: GENERAL CONCEPTS
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Chapter 21 Cancer and the Immune System Dr. Capers
Nanocell: Mechanism of action
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
Group Number: 2 Britney Porter, Sandra Nguyen, Eduardo Vargas and Samender Singh Randhawa.
Non-Communicable Diseases
Cancer Treatment Ashley Panakezham Rosemin Panjwani Osman Jamal Mustafa Quraishi.
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
Antibody and prodrug therapy of cancer
Par-4 Induced Apoptosis By Ashley Feng and Lilly Holman Par-4 Induced Apoptosis By Ashley Feng and Lilly Holman Par-4 Overexpression of the prostate apoptosis.
Cell Cycle and Cancer.
The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats Hala O El Mesallamy, Nadia S Metwally2, Mahmoud.
Lesson Overview Lesson Overview Regulating the Cell Cycle Lesson Overview 10.3 Regulating the Cell Cycle.
10.3 Regulating the Cell Cycle
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
HDAC6 : HDAC6 is a cytoplasmic enzyme that regulates many important biological processes. : HDAC6 has recently emerged as a tubulin deacetylase that has.
Cell Suicide in Health and Disease
Effects of metformin and thymoquinone on survival of leukemic cells
Presented by: Dr/Fedaa Abd-Elmonem Clinical pharmacy instructor Tanta University.
10.3-Regulating the Cell Cycle Controls on Cell Division The cell cycle is controlled by regulatory proteins both inside and outside the cell. Cyclins.
MITOSIS: CELL CYCLE CONTROL. OVERVIEW: Has 4 phases – G 1, S, G 2, and M Driven by specific molecular signals present in the cytoplasm Controlled by a.
BASIS OF CANCER CHEMOTHERAPY PHL 417 Dr. Mohamed M. Sayed-Ahmed.
Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.
Ch.10-3 Regulating the Cell Cycle. POINT > Identify 3 reasons cells divide POINT > Describe the role of cyclins in cell division POINT > Identify other.
The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.
Mitochondrial Retrograde Signaling Mediated by UCP2 Inhibits Cancer Cell Proliferation and Tumorigenesis 석사 1 학기 Tran Phuong Thao.
التأثير العلاجي لمستحضرات صيدلية مبتكرة لسم النحل علي نموذج الورم الصلب Clinical Pharmacist: Maha Nasify Ali Mohammad, MSc Al Mosalami center for treating.
 Chemotherapy is a common strategy used to kill cancer cells.  However toxicity of chemotherapy drugs to normal cells limits their application.
Cancer and the Immune System
Regulation of the Cell Cycle
Cell Cycle Regulation.
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
Multidrug resistance drives partial EMT to complete EMT: study the network of EMT mediators 楊毅輝1*、陳奇雍2、孟子青3、王正康4# 1國所防醫學院醫學系,2國防醫學院生命科學研究所,3國防醫學院生物化學研究所,4中央研究院生物化學研究.
(vi) AMI+Rotenone H&E X 20
Uncontrolled Cell Division and Differentiation
FASTING INHIBITS THE GROWTH OF CANCER CELLS INVOLVES P53
Background and Objectives:
“The Life and Times of the Cell”
Antitumour Antibiotics PHL 417
Regulating the Cell Cycle
Par-4 Induced Apoptosis
10-3 Regulating the Cell Cycle
Figure 1 Simplified representation of the physiological
10.3 Regulating the Cell Cycle
Cancer: When The Cell Cycle Goes Wrong
Heather L Maecker, Zhong Yun, Holden T Maecker, Amato J Giaccia 
Molecular Therapy - Nucleic Acids
Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis  Shinji Tanaka, Jack R. Wands, Shigeki.
Apoptosis Cell Volume 108, Issue 2, Pages (January 2002)
Table 1. Bioactive properties in Coriolus versicolor
Apoptosis: Activate NF-κB or die?
Mohammed Charbat.
Presentation transcript:

T argeting S phingosine K inase 1 and A poptosis by M etformin to D ecrease T umor R esistance to A driamycin By Dr. Ahmed Mohamed Kabel Pharmacology Department, Faculty of Medicine, Tanta University, Egypt Pharmacology Department, College of Pharmacy, Taif University, KSA

Adriamycin (ADR, Doxorubicin) is an anthracycline antibiotic that is frequently used as a treatment for many types of cancer such as leukemia, lymphoma, breast, ovarian and lung cancer. It damages DNA by intercalation into DNA and inhibition of topoisomerase II resulting in DNA strand breaks.

The major limiting factor for the use of ADR in cancer therapy is the development of resistance. The mechanisms of this resistance may include increased activity of sphingosine kinase-1 (SphK1) enzyme which inhibits penetration and intercalation of ADR into DNA and significantly abolishing the anticancer effect of ADR. This makes it essential to combine ADR with agents that inhibit these mechanisms to decrease the incidence of resistance of cancer cells to ADR.

Metformin is an antidiabetic agent that decreases intestinal absorption of glucose, increases its anaerobic metabolism and improves insulin sensitivity. Studies on animal models had demonstrated that metformin prevents tumor development and inhibits cell proliferation. This effect may be mediated through its regulatory role on the hormonal, metabolic and immune functions.

The main molecular target of metformin is AMP- activated protein kinase (AMPK) signaling that plays a crucial role in the control of cell division and proliferation. Moreover, metformin had been shown to improve endothelial function, decrease inflammatory response, and regulate immune functions which have a major role in the pathogenesis of cancer. Also, metformin was proven to inhibit SphK1 activity which was one of the main factors contributing to resistance of cancer cells to chemotherapy.

So, The aim of this work was to study the effect of targeting sphingosine kinase 1 and apoptosis by metformin on tumor resistance to adriamycin using a transplantable tumor model in mice.

In this study, we used a model of solid Ehrlich carcinoma (SEC), where Ehrlich carcinoma cells (ECCs) were implanted subcutaneously into the right thigh of the hind limb of mice. A palpable solid tumor mass (about 100 mm 3 ) was developed within 10 days.

Ehrlich Ascites Carcinoma Used for induction of SEC Ehrlich Ascites Carcinoma Used for induction of SEC

Control SEC

One hundred BALB/C mice were divided into 5 equal groups of twenty mice each as follows: Group (1): the Control untreated group Group (2): ECCs were implanted subcutaneously into the right thigh of the hind limb of mice. Group (3): Adriamycin was given by intra-tumoral injection on days 10, 15, 20, 25, 30 and 35 after implantation of ECCs.

Group (4): Metformin was given to mice orally starting 10 days after implantation of ECCs and continued for 32 days. Group (5): Adriamycin and metformin were given together starting 10 days after implantation of ECCs and continued for 32 days by the above regimens.

Tumor volume was measured on days 15, 20, 25, 30, 35 and 40 after implantation of ECCs. In the 42nd day after implantation of ECCs, the animals were killed and the tumor was excised and divided into two portions: one for homogenization and the other for histopathological examination. The tumor tissue was homogenized for determination of tissue catalase, glutathione reductase, malondialdehyde, sphingosine kinase 1 activity, caspase 3 activity and tumor necrosis factor alpha.

Effect of different treatments on tumor volume a Significant compared to SEC group (P < 0.05). b Significant compared to SEC+ADR group (P < 0.05). c Significant compared to SEC+Metformin group (P < 0.05). Effect of different treatments on tumor volume a Significant compared to SEC group (P < 0.05). b Significant compared to SEC+ADR group (P < 0.05). c Significant compared to SEC+Metformin group (P < 0.05).

Effect of different treatments on tissue antioxidant parameters

Effect of different treatments on tissue TNF- α

Effect of different treatments on tissue caspase 3 activity

Effect of different treatments on tissue SphK1 activity

Effect of different treatments on the apoptotic index

H&E stained sections of a) SEC showing sheets of small tumor cells representing cell proliferation surrounding areas of necrosis; b) ADR group showing focal necrosis with sheets of malignant cells; c) Metformin showing focal necrosis; d) ADR/metformin combination group showing extensive necrosis. H&E stained sections of a) SEC showing sheets of small tumor cells representing cell proliferation surrounding areas of necrosis; b) ADR group showing focal necrosis with sheets of malignant cells; c) Metformin showing focal necrosis; d) ADR/metformin combination group showing extensive necrosis.

A photomicrograph of a) SEC group showing negative staining for p53; b) ADR group showing positive (+++) p53 expression; c) Metformin group showing positive (++) p53 expression; d) ADR/metformin group showing positive (++++) p53 expression. A photomicrograph of a) SEC group showing negative staining for p53; b) ADR group showing positive (+++) p53 expression; c) Metformin group showing positive (++) p53 expression; d) ADR/metformin group showing positive (++++) p53 expression.

The combination of ADR and metformin had a better effect than each of these drugs alone against transplantable tumor model in mice. Conclusions This might be due to the combined antioxidant and anti-inflammatory properties of both drugs together with their ability to induce apoptosis of cancer cells. Moreover, metformin was able to decrease SphK1 enzyme activity which potentiates the effect and decreases resistance of cancer cells to ADR.

So, it is recommended to add metformin to the anti-cancer regimens containing ADR to decrease resistance of cancer cells to ADR.